UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 245

Sortiert nach

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-08, Vol.377 (9), p.829-838

2017

Link zum Volltext

Verfügbarkeit prüfen

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

Clinical cancer research, 2018-07, Vol.24 (14), p.3334-3347

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Cancer treatment reviews, 2018-12, Vol.71, p.59-67

2018

Link zum Volltext

Verfügbarkeit prüfen

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases

Cancer treatment reviews, 2014-07, Vol.40 (6), p.716-722

2014

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis

Lung cancer (Amsterdam, Netherlands), 2021-08, Vol.158, p.97-106

2021

Link zum Volltext

Verfügbarkeit prüfen

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1233-1243

2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of Wnt1, Wnt2, E-Cadherin, and β-catenin Expression in Operable Non-small Cell Lung Cancer

The journal of histochemistry and cytochemistry, 2021-11, Vol.69 (11), p.711-722

2021

Link zum Volltext

Verfügbarkeit prüfen

Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer

The lancet respiratory medicine, 2020-06, Vol.8 (6), p.528-529

2020

Link zum Volltext

Verfügbarkeit prüfen

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

Journal of clinical oncology, 2015-03, Vol.33 (9), p.992-999

2015

Link zum Volltext

Verfügbarkeit prüfen

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents

Translational lung cancer research, 2021-04, Vol.10 (4), p.2032-2047

2021

Link zum Volltext

Verfügbarkeit prüfen

Complex EGFR mutations in non-small cell lung cancer: a distinct entity?

Journal of thoracic disease, 2022-08, Vol.14 (8), p.2738-2741

2022

Link zum Volltext

Verfügbarkeit prüfen

Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement

International journal of radiation oncology, biology, physics, 2020-07, Vol.107 (4), p.631-640

2020

Link zum Volltext

Verfügbarkeit prüfen

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

The lancet oncology, 2013-09, Vol.14 (10), p.916-917

2013

Link zum Volltext

Verfügbarkeit prüfen

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

Medical science monitor, 2017-03, Vol.23, p.1208-1216

2017

Link zum Volltext

Verfügbarkeit prüfen

APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. EORTC 1613

Clinical lung cancer, 2017-09, Vol.18 (5), p.583-588

2017

Link zum Volltext

Verfügbarkeit prüfen

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

ESMO open, 2020-01, Vol.5 (Suppl 3), p.e000820, Article e000820

2020

Link zum Volltext

Verfügbarkeit prüfen

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer

Journal of thoracic oncology, 2016-08, Vol.11 (8), p.1273-1281

2016

Link zum Volltext

Verfügbarkeit prüfen

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain

Breast cancer research : BCR, 2012-08, Vol.14 (4), p.R119-R119, Article R119

2012

Link zum Volltext

Verfügbarkeit prüfen

STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues

Journal of thoracic oncology, 2022-03, Vol.17 (3), p.351-352

Dziadziuszko, Rafal

2022

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.110-120

2017

Link zum Volltext

Verfügbarkeit prüfen

Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review

Translational lung cancer research, 2023-03, Vol.12 (3), p.594-614

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2006-11, Vol.24 (31), p.5034-5042

2006

Link zum Volltext

Verfügbarkeit prüfen

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

International journal of molecular sciences, 2023-05, Vol.24 (11), p.9165

2023

Link zum Volltext

Verfügbarkeit prüfen

Profound neutropenia related to consolidation durvalumab treatment following concurrent radiochemotherapy in a patient with stage III non-small‑cell lung cancer

Polskie archiwum medycyny wewne̦trznej, 2022-02, Vol.132 (2)

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 245

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(220)
Mit Volltextzugriff
(233)

Publikationsform

Sprache

Englisch
(237)
Japanisch
(32)
Polnisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(150)
Life Sciences & Biomedicine
(149)
Humans
(124)
Oncology
(120)
Female
(67)
Middle Aged
(60)
Male
(58)
Respiratory System
(55)
Aged
(52)
Lung Neoplasms - Genetics
(51)
Lung Neoplasms - Pathology
(45)
Adult
(44)
Lung Neoplasms - Drug Therapy
(42)
Carcinoma, Non-Small-Cell Lung - Genetics
(41)
Lung Cancer
(39)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(37)
Prognosis
(33)
Carcinoma, Non-Small-Cell Lung - Pathology
(29)
Biological And Medical Sciences
(27)
Medical Sciences
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases

Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Prognostic Significance of Wnt1, Wnt2, E-Cadherin, and β-catenin Expression in Operable Non-small Cell Lung Cancer

Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents

Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement

Complex EGFR mutations in non-small cell lung cancer: a distinct entity?

Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. EORTC 1613

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain

STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer

Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

Profound neutropenia related to consolidation durvalumab treatment following concurrent radiochemotherapy in a patient with stage III non-small‑cell lung cancer

Suchergebnisse filtern